Medifast Reports Steep Revenue Decline Amid GLP-1 Pressure
Event summary
- Revenue dropped 27.6% YoY to $76.4M in Q2 2026 due to a 48.7% decline in active earning coaches
- Net loss of $3.1M ($0.28 EPS) compared to net income of $2.5M ($0.22 EPS) in Q2 2025
- Revenue per coach increased 41% YoY to $6,529 as company focuses on productive coaches
- Launched Trilivy Reset product line and Catalyst cost-saving program in Q2
The big picture
Medifast's Q2 results reflect broader challenges facing traditional weight loss programs against GLP-1 competitors. The company's strategic shift toward metabolic health and coach network optimization aims to restore profitability by Q4, but sustained declines in active coaches pose execution risks. With $169.8M in cash reserves and no debt, Medifast has financial flexibility for its transformation, though the path to long-term growth remains uncertain.
What we're watching
- GLP-1 Competition
- Whether Medifast can mitigate ongoing pressure from GLP-1 weight loss medications affecting client acquisition.
- Cost Savings Execution
- The pace at which the Catalyst program delivers promised efficiencies through facility rationalization and AI.
- Coach Network Stability
- How further declines in active earning coaches will impact revenue trajectory despite productivity gains.